Drug Database
Back to search

Switzerland· 53563015

Wellvone, Suspension

A atovaquone product containing atovaquonum, registered in Switzerland by GlaxoSmithKline AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC P01AX06

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedWellvone, SuspensionATCP01AX06REGISTER NO.53563015PACKS LISTED1CHECKEDSeptember 12, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about atovaquonumAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Atovaquone is registered in 11 of 19 countries.

Countries holding a registration under ATC P01AX06 (atovaquone), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 5 of them publish a price we can compare per daily dose
Search atovaquone products by name

Atovaquone · ATC P01AX06

11 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Franceprice
  • Germany
  • Netherlands
  • Norwayprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Swissmedic (Switzerland)
Active substance
atovaquonum
Manufacturer
GlaxoSmithKline AG
Country
Switzerland (CH)
ATC code
P01AX06
ATC class
Atovaquone
Defined daily dose
1.5 g, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680535630151
    210 ml
    CHF 429.6

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

182 interactions on record for atovaquone.

Graded by severity as the source publishes them — 8 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check atovaquone against other medicinesHow interaction checks work

Atovaquone · interactions on record

182 records

  • 8 severe
  • 32 moderate
  • 4 minor
  • 133 info

Most severe, free to view

  • MipomersenC10AX11severe
  • LomitapideC10AX12severe
  • EfavirenzJ05AG03severe
  • PexidartinibL01EX15severe

5 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Atovaquone in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All atovaquone products

Authorised across Europe · EMA

The same active substance is authorised in 13 EEA countries. Names it is sold under:

  • Belgium · Wellvone
  • Germany · Atovaquon Glenmark, Wellvone
  • Denmark · Atovaquone Glenmark
  • Spain · Atovacuona Glenmark, Wellvone
  • France · Atovaquone Biogaran, Wellvone
  • United Kingdom (Northern Ireland) · Atovaquone Amarox, Atovaquone Glenmark Pharmaceuticals Europe
  • Greece · Atovaquone Vocate, Wellvone
  • Italy · Atovaquone Glenmark, Wellvone
  • Luxembourg · Wellvone
  • Netherlands · Atovaquon Glenmark, Wellvone
  • Norway · Atovaquone Glenmark
  • Portugal · Atovaquona Kabi, Wellvone
  • Sweden · Atovaquone Glenmark, Wellvone

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/6a9e7851-d1ac-4208-9c67-90a2082c392e
GET /v1/drugs/6a9e7851-d1ac-4208-9c67-90a2082c392e?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "atovaquonum 750 mg",
  "valid_from": "1997-03-15",
  "limitations": "[{\"description\":\"Behandlung einer akuten, leichten bis mittelschweren (alveolärer-arterieller Sauerstoffgradient (A-a)DO2 = 45 mm Hg 6kPa und arterieller Sauerstoffdruck PaO2 >= 60mm Hg 8kPa bei eingeatmeter Zimmerluft) Pneumocystis carinii Pneumonie (PCP) bei Patienten, die überempfindlich auf eine Cotrimoxazol-Therapie sind.\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2007-01-01\"}]",
  "galenic_form": "Susp 750 mg/5ml",
  "therapeutic_area": null,
  "sl_inclusion_date": "1997-03-15",
  "self_retention_pct": 10
}
API referenceMCP serverPlans

See everything about atovaquone.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console